Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor

被引:20
作者
Bain, Gretchen [1 ]
King, Christopher D. [1 ]
Schaab, Kevin
Rewolinski, Melissa [2 ]
Norris, Virginia [3 ]
Ambery, Claire [3 ]
Bentley, Jane [3 ]
Yamada, Masanori [4 ]
Santini, Angelina M. [1 ]
de Rooij, Jeroen van de Wetering [5 ]
Stock, Nicholas [6 ]
Zunic, Jasmine
Hutchinson, John H. [7 ]
Evans, Jilly F.
机构
[1] Bristol Myers Squibb, San Diego, CA 92121 USA
[2] Intercept Pharmaceut, San Diego, CA USA
[3] GSK, Stevenage, Herts, England
[4] GSK, Tokyo, Japan
[5] PRA Int Grp BV, Zuidlaren, Netherlands
[6] Incept Sci, San Diego, CA USA
[7] Brain Cells Inc, San Diego, CA USA
关键词
asthma; FLAP; GSK2190915; leukotrienes; pharmacodynamics; pharmacokinetics; INDUCED AIRWAY RESPONSES; LEUKOTRIENE BIOSYNTHESIS; INFLAMMATORY DISEASES; ALLERGEN CHALLENGE; ASTHMATIC SUBJECTS; FLAP; GENERATION; MK-0591; LTA4H; RISK;
D O I
10.1111/j.1365-2125.2012.04386.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim To assess the pharmacokinetics, pharmacodynamics, safety and tolerability of the 5-lipoxygenase-activating protein inhibitor, GSK2190915, after oral dosing in two independent phase I studies, one in Western European and one in Japanese subjects, utilizing different formulations. Method Western European subjects received single (501000mg) or multiple (10450mg) oral doses of GSK2190915 or placebo in a dose-escalating manner. Japanese subjects received three of four GSK2190915 doses (10200mg) plus placebo once in a four period crossover design. Blood samples were collected for GSK2190915 concentrations and blood and urine were collected to measure leukotriene B4 and leukotriene E4, respectively, as pharmacodynamic markers of drug activity. Results There was no clear difference in adverse events between placebo and active drug-treated subjects in either study. Maximum plasma concentrations of GSK2190915 and area under the curve increased in a dose-related manner and mean half-life values ranged from 1634h. Dose-dependent inhibition of blood leukotriene B4 production was observed and near complete inhibition of urinary leukotriene E4 excretion was shown at all doses except the lowest dose. The EC50 values for inhibition of LTB4 were 85nm and 89nm in the Western European and Japanese studies, respectively. Conclusion GSK2190915 is well-tolerated with pharmacokinetics and pharmacodynamics in Western European and Japanese subjects that support once daily dosing for 24h inhibition of leukotrienes. Doses of 50mg show near complete inhibition of urinary leukotriene E4 at 24h post-dose, whereas doses of 150mg are required for 24h inhibition of blood LTB4.
引用
收藏
页码:779 / 790
页数:12
相关论文
共 32 条
[21]   Discovery of AZD6642, an Inhibitor of 5-Lipoxygenase Activating Protein (FLAP) for the Treatment of Inflammatory Diseases [J].
Lemurell, Malin ;
Ulander, Johan ;
Winiwarter, Susanne ;
Dahlen, Anders ;
Davidsson, Oejvind ;
Emtenaes, Hans ;
Broddefalk, Johan ;
Swanson, Marianne ;
Hovdal, Daniel ;
Plowright, Alleyn T. ;
Pettersen, Anna ;
Ryden-Landergren, Marie ;
Barlind, Jonas ;
Llinas, Antonio ;
Hersloef, Margareta ;
Drmota, Tomas ;
Sigfridsson, Kalle ;
Moses, Sara ;
Whatling, Carl .
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (02) :897-911
[22]   Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects [J].
Johansson, S. ;
Cullberg, M. ;
Eriksson, U. G. ;
Elg, M. ;
Duner, K. ;
Jensen, E. ;
Wollbratt, M. ;
Wahlander, K. .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (04) :258-267
[23]   5-lipoxygenase-dependent biosynthesis of novel 20:4 n-3 metabolites with anti-inflammatory activity [J].
Gagnon, K. J. ;
Lefort, N. ;
Poirier, S. J. ;
Barnett, D. A. ;
Surette, M. E. .
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2018, 138 :38-44
[24]   Anti-allergic, anti-asthmatic and anti-inflammatory effects of an oxazolidinone hydroxamic acid derivative (PH-251)-A novel dual inhibitor of 5-lipoxygenase and mast cell degranulation [J].
Ezeamuzie, Charles, I ;
Rao, Muddanna S. ;
El-Hashim, Ahmed Z. ;
Philip, Elizabeth ;
Phillips, Oludotun A. .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 105
[25]   THE EFFECT OF MK-0591, A NOVEL 5-LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR, ON LEUKOTRIENE BIOSYNTHESIS AND ALLERGEN-INDUCED AIRWAY RESPONSES IN ASTHMATIC SUBJECTS IN-VIVO [J].
DIAMANT, Z ;
TIMMERS, MC ;
VANDERVEEN, H ;
FRIEDMAN, BS ;
DESMET, M ;
DEPRE, M ;
HILLIARD, D ;
BEL, EH ;
STERK, PJ .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1995, 95 (01) :42-51
[26]   Randomized, double-blinded, placebo-controlled phase I study of the pharmacokinetics, pharmacodynamics, and safety of KL130008, a novel oral JAK inhibitor, in healthy subjects [J].
Li, Na ;
Du, Shuangqing ;
Wang, Ying ;
Zhu, Xiaohong ;
Shu, Shiqing ;
Men, Yuchun ;
He, Miao ;
Fang, Fang ;
Wang, Yongsheng ;
Gong, Yimou ;
Chen, Jing ;
Gu, Liling ;
Cheng, Yezhe ;
He, Qiang ;
Lu, Huifang ;
Niu, Yuanyuan ;
Xu, Ying ;
Feng, Ping .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 176
[27]   5-Lipoxygenase-Activating Protein (FLAP) Inhibitors. Part 4: Development of 3-[3-tert-Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic Acid (AM803), a Potent, Oral, Once Daily FLAP Inhibitor [J].
Stock, Nicholas S. ;
Bain, Gretchen ;
Zunic, Jasmine ;
Li, Yiwei ;
Ziff, Jeannie ;
Roppe, Jeffrey ;
Santini, Angelina ;
Darlington, Janice ;
Prodanovich, Pat ;
King, Christopher D. ;
Baccei, Christopher ;
Lee, Catherine ;
Rong, Haojing ;
Chapman, Charles ;
Broadhead, Alex ;
Lorrain, Dan ;
Correa, Lucia ;
Hutchinson, John H. ;
Evans, Jilly F. ;
Prasit, Peppi .
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (23) :8013-8029
[28]   Pharmacological Characterization of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionicAcid (AM103), a Novel Selective 5-Lipoxygenase-Activating Protein Inhibitor That Reduces Acute and Chronic Inflammation [J].
Lorrain, Daniel S. ;
Bain, Gretchen ;
Correa, Lucia D. ;
Chapman, Charles ;
Broadhead, Alex R. ;
Santini, Angelina M. ;
Prodanovich, Pat ;
Darlington, Janice V. ;
Hutchinson, John H. ;
King, Christopher ;
Lee, Catherine ;
Baccei, Christopher ;
Li, Yiwei ;
Arruda, Jeannie M. ;
Evans, Jilly F. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 331 (03) :1042-1050
[29]   Preclinical Pharmacokinetics and Acute Toxicity in Rats of 5-{[(2E)-3-Bromo-3-carboxyprop-2-enoyl]amino}-2-hydroxybenzoic Acid: A Novel 5-Aminosalicylic Acid Derivative with Potent Anti-Inflammatory Activity [J].
Gutierrez-Sanchez, Mara ;
Romero-Castro, Aurelio ;
Correa-Basurto, Jose ;
Rosales-Hernandez, Martha Cecilia ;
Padilla-Martinez, Itzia Irene ;
Mendieta-Wejebe, Jessica Elena .
MOLECULES, 2021, 26 (22)
[30]   5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)-A potent FLAP inhibitor suitable for topical administration [J].
Stock, Nicholas ;
Baccei, Christopher ;
Bain, Gretchen ;
Chapman, Charles ;
Correa, Lucia ;
Darlington, Janice ;
King, Christopher ;
Lee, Catherine ;
Lorrain, Daniel S. ;
Prodanovich, Pat ;
Santini, Angelina ;
Schaab, Kevin ;
Evans, Jilly F. ;
Hutchinson, John H. ;
Prasit, Peppi .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (15) :4598-4601